CSL Ltd (ASX: CSL) has long been lauded as a shining example of homegrown Australian ingenuity succeeding on a world stage, and as such, has been a mainstay in many investors' portfolios. The ...

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst ...

Spencer Pratt keeps hitting back against his loudest critics. Pratt, who originally rose to fame as a reality star on "The Hills," has been receiving a lot of attention for his move to politics. He's ...

Adrian has been writing, critiquing, and thinking about games since he first picked up an N64 controller many years ago. These days he writes reviews, news, and features for Game Rant and believes ...

CSL has sliced its revenue projection for FY 2026 from $15.8 billion to $15.2 billion in another indication of the Australian company’s financial distress since its 2022 acquisition of Vifor Pharma. ( ...

For customers willing to pay for it, the new top plan offers more high-speed data and performance than the former one. Jeff Carlson writes about mobile technology for CNET. He is also the author of ...

The Road to Indianapolis is set with the 2026 Elite Eight. The remaining teams in the Men's NCAA Tournament will go head-to-head in hopes of advancing one step closer to making that trip to Lucas Oil ...

Davos has become a symbol of global elites — and a constant target for conservative criticism. But behind the rhetoric lies a deeper contradiction: many of the same figures who condemn these ...

A CSL manufacturing expansion, tipped to come online by 2031, will create at least 300 new direct jobs at its facility in Kankakee, Illinois, adding to the site’s current workforce of more than 1,200.

BRADLEY, Ill. -- Australian biopharmaceutical company CSL announced Monday a major expansion at its Kankakee manufacturing facility, a move that will bring end-to-end plasma processing into the U.S.

Illinois Gov. JB Pritzker on Monday announced a $1.5 billion investment from biotherapeutics company CSL for a new plasma therapy manufacturing plant in Kanakee. CSL will expand its current footprint ...

CSL granted Eli Lilly certain rights for clazakizumab CSl to receive upfront payment of $100 million CSL shares up 2.1% CSL will retain exclusive rights to develop and commercialise clazakizumab for ...